Please wait a minute...
TMR Modern Herbal Medicine  2018, Vol. 1 Issue (3): 171-180    DOI: 10.12032/TMRmhm2017B23
Review     
Kangfuxin Fluid on the Treatment of Ulcerative Colitis with Retention Enema: a Systematic Review
Yang Si-Yuan1, Jia Yuan1, Guo Li-Min1, Meng Fan-Jie1,*()
1 Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Download: HTML     PDF(549KB)
Export: BibTeX | EndNote (RIS)      

Objective: To systematically evaluate the effectiveness of Kangfuxin Fluid (KFX) in Ulcerative Colitis (UC) with retention enema. Methods: We searched The Cochanrane Library, Pubmed, EMbase, VIP, CNKI, CBM and WanFang Data from inception to December.2017, and retrospectively incorporated into the literature reference. And a systematic review of randomized controlled trials was performed. Meta-analysis was performed with RevMan5.3 software. Results: A total of 18 randomized controlled trials and 1417 patients were enrolled, among which 731 cases were in experimental group and 686 cases were in control group. The meta-analysis results revealed that the effectiveness of KFX on UC with retention enema was significantly superior to the controlled treatment (RR=1.22 95%CI: [1.16,1.27], Z=8.14, p<0.00001). And, the score of quality of life was significantly increased after KFX treatment (MD=11.12, 95% CI [7.00, 15.23], Z=5.30, p<0.00001). Conclusion: KFX on the treatment of UC with retention enema is potentially effective to improve patient's quality of life, and it is worth being popularized clinically. Depth researches and high quality randomized controlled trials on the efficacy of UC are necessary.

Highlights

Nowadays, the treatment of Ulcerative Colitis remains complex. Kangfuxin Fluid, a kind of Chinese traditional medicine, which efficacy is evaluated in this meta-analysis on the treatment of Ulcerative Colitis with retention enema based on the latest and most available supports. According to those supportive data, Kangfuxin Fluid is potentially affective to improve the treatment of patients with Ulcerative Colitis, and it is worth being popularized clinically. Meanwhile, in-depth researches and high quality randomized controlled trials are still in need. We have systematically reviewed the final vision of the manuscript and plunk for the publication. To the best of our knowledge and belief, this manuscript has not been published in whole or in part nor considered for publication elsewhere.



Key wordsKangfuxin Fluid      Ulcerative Colitis      Retention enema      Systematic Review     
Received: 29 June 2018      Published: 25 July 2018
Corresponding Authors: Meng Fan-Jie     E-mail: mfj1127@126.com
Cite this article:

Yang Si-Yuan, Jia Yuan, Guo Li-Min, Meng Fan-Jie. Kangfuxin Fluid on the Treatment of Ulcerative Colitis with Retention Enema: a Systematic Review. TMR Modern Herbal Medicine, 2018, 1(3): 171-180. doi: 10.12032/TMRmhm2017B23

URL:

https://www.tmrjournals.com/mhm/EN/10.12032/TMRmhm2017B23     OR     https://www.tmrjournals.com/mhm/EN/Y2018/V1/I3/171

Figure1. Study flow diagram
Study Number
(T/C)
Age
(T/C)
Course of disease(year) Intervention Control Course of treatment(d) Outcomes
Lv
2003[15]
21/10 45.6 0.5-12 KFX Yunnan Baiyao
+Xilei Power
47
Dai
2010[16]
71/62 17-68/19-63 0.5-7 KFX Yunnan Baiyao
+Xilei Power
28
Ai
2010[17]
35/21 33.2±5.56 /34.16±4.82 0.5-15/0.6-13 KFX50ml Xilei Power+
Metronidazole
+Berberine
20
Zhou
2010[18]
20/19 37.5 1-15 KFX SSZ 20
Ding
2011[19]
60/60 41.5 0.4-11 KFX SASP 30
Liang
2011[20]
76/60 42.5/40.1 0.3-9 KFX Xilei Power
+dexamethasone
28
Liu Jian
2011[21]
39/38 28.2±3.2/30.2±3.6 - KFX 5-ASA 14 ①②⑦
Liu fengjiao
2012[22]
15/15 46.2 1-4 KFX Yunan Baiyao
+Xilei Power
30 ①⑦
Gao
2012[23]
23/20 39 1-15 KFX gentamicins 15
Pan
2012[24]
40/40 45.8/46.2 - KFX SSZ+folic acid 56 ①④⑤⑥
Lv weina
2012[25]
80/80 - 15d-12 KFX SSZ 30
Liu Qi
2013[26]
17/17 46.0±3.2/45.0±2.5 5.24±1.71/5.31±1.86 KFX Hydrocortisone
+lidocaine
+gentamicins
28 1③
Li yuerong
2013[27]
43/42 35.6±4.2/35.1±5.4 0.5-11/0.5-10 KFX Yunnan Baiyao
+Xilei Power
20
Liu Yi
2013[28]
32/32 34.3±6.6/35.1±6.8 0.3-12/0.6-10 KFX Metronidazole
+dexamethasone
+gentamicins
20
Liu renmiao
2013[29]
40/40 32.2±12.8 - KFX mesalazine 15
Wei
2013[30]
65/65 - 1.5-26 KFX Smetca 35
Kang
2014[31]
20/20 53 - KFX Xilei Power
+gentamicins+
dexamethasone
-
Zheng
2017[32]
35/35 28.4±3.3 / 27.6±3.5 - KFX 5-ASA 14 ①②⑦
Table 1 Characteristics of studies
Figure2. Graph of risk of bias.
Figure3. Summary of risk of bias
Figure4. Effective rate of KFX on the treatment of UC with retention enema
Figure5. Quality of life scores
Figure.6 Recurrence rate of Kangfuxin Fluid treating the UC with retention enema
Figure 7. Meta-analysis of inverted funnel plot
1   Eugène. C.Ulcerative Colitis practice guideline in adults. Clin Res Hepatol Gastroenterol 2012, 36: 107-109.
doi: 10.1016/j.clinre.2011.09.013 pmid: 22236738
2   Molodecky NA, Soon IS, Rabi DM, et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterol 2012 ,142: 46-54.
doi: 10.1053/j.gastro.2011.10.001
3   Ye L, Cao Q, Cheng J.Review of inflammatory bowel disease in China. ScientificWorldJournal 2013, 14: 296470.
doi: 10.1155/2013/296470 pmid: 24348149
4   Zheng HB.The Comparation of Global Occurrence of Ulcerative Colitis. Chin J Dig 2001, 21: 242-243.
5   Nundhini, Thukkani, J Lucas, et.al, Incidence and prevalence of inflammatory bowel disease in Japan: nationwide epidemiological survey during the year 1991. Inflamm Bowel Dis 2011, 17: 1333-1337.
doi: 10.1002/ibd.21513 pmid: 21560196
6   KT Thia, EV Loftus, WJ Sandborn, et al.An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008, 103: 3167-3182.
doi: 10.1111/j.1572-0241.2008.02158.x pmid: 19086963
7   Huang NJ. Chinese Anorectal Disease. 1st ed.Shandong: Shandong Science and Technology Press, 1996: 998.
8   Xie ZL, Analysis of treatment of drug enema for ulcerative colitis of 89 Patients. Jilin Med J 2011, 32: 6617-6618.
9   Huang XQ.Treatment of Gastrointestinal Diseases. 1st ed.Tianjin: Tianjin science and Technology Press, 1996: 674-677.
10   Rui YC. Modern Pharmacology.1st ed, Beijing: People's Military Medical Publishing House, 1999: 780-782.
11   Deng CS, Xia B. Inflammatory Bowel Disease.1st ed.Beijing: People's Medical Publishing House, 1998: 265-267.
12   Higgins J P T,Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[M/OL]. (2011-03-01) [2015-05-01] The Coochrane Collaboration, 2011. .
13   China National Chinese medicine anorectal Branch. Therapeutic criteria for ulcerative colitis. J Middle Anorectal Dis 1998, 8: 42.
14   Qin OY, Pan GZ, Wen ZH, Recommendations for the Diagnosis and Treatment of Inflammatory Bowel Disease. Gastroenterol 2001, 15: 138-138.
15   Lv W. Observation of Clinical Effect of Kangfuxin Fluid on Ulcerative Colitis with Retention Enema. Chin Compr Clin 2003, 19: 912-913.
16   Dai JH. Observation of Effect of Kangfuxin Fluid on Ulcerative Colitis with Retention Enema. Mod Med Health 2010, 9: 8865-8866.
17   Ai MJ. Observation and Nursing of Kangfuxin Fluid on Ulcerative Colitis with Retention Enema. China Contemp Med 2010 3: 188-189.
18   Zhou CL. Observation and Nursing of Kangfuxin Fluid on Ulcerative Colitis with Retention Enema. Chin General Med 2010, 08: 1474-1475.
19   Ding Y. 60 Samples of Ulcerative Colitis Treatment by Kangfuxin Fluid. Chin J Integr Tradit Chin Western Med 2011, 19: 129-130.
20   Liang HR. Observation and Nursing of Kangfuxin Fluid on Ulcerative Colitis with Retention Enema. Mod Med Health 2011, 27: 2347-2348.
21   Liu J. The Observation of Clinic Effect of Kangfuxin Fluid on Ulcerative Colitis. Chin Hosp Pharm J 2011,31: 1888-1892.
22   Liu FJ. The Observation of Clinic Effect of Kangfuxin Fluid on Ulcerative Colitis. Chin Med Guide 2012, 10: 216-217.
23   Gao W. The Understanding of Nursing the Ulcerative Colitis Patient under the Treatment of the Kangfuxin Fluid. J Med Theory Pract 2012, 25: 1509-1510.
24   Pan W. 40 Examples of Treating Ulcerative Colitis by Kangfuxin Fluid. Shanxi Tradi Chin Med 2012,33: 1125-1127.
25   Lv WN. The Observation of Clinic Effect of Kangfuxin Fluid on Ulcerative Colitis with Enema, Chin Med Guide 2012: 599-599.
26   Li Q. The Observation of Clinic Effect of Kangfuxin Fluid on Ulcerative Colitis with Enema. Qinghai Med J 2013,13: 87-87.
27   Li YR. The Observation of Clinic Effect of Kangfuxin Fluid on Ulcerative Colitis. J Clin Rational Use Drugs 2013, 6: 56-56.
28   Liu Y. The Observing and Nursing 32 Examples under the Treatment of Kangfuxin Fluid on Ulcerative Colitis with Enema. China Pharm 2013, 22: 106-106.
29   Liu RM. The Observation of Clinic Effect of 40 Ulcerative Colitis Patients under the treatment of Kangfuxin Fluid. Chin Folk Med 2013, 22: 64-64.
30   Wei XX. The Clinic Research of Kangfuxin Fluid on Ulcerative Colitis with Enema. Jilin Med 2013, 34: 5388-5389.
31   Kang HJ. The Nursing Understanding of Ulcerative Colitis Patients under the treatment of Kangfuxin Fluid with Enema. Chin Community Doctors 2014,1: 138-138.
32   Zheng XX. The Clinic Observation of 70 Ulcerative Colitis Patients under the treatment of Kangfuxin Fluid. Women's Health Res 2017,2: 39-40.
33   Vagefi PA, Longo WE. Colorectal cancer in patients with inflammatory bowel disease. Clin Colorectal Cancer 2005, 4: 313-319.
doi: 10.3816/CCC.2005.n.003
34   Li SZ. Compendium of Materia Medica. 1st ed. Beijing: People's Medical Publishing House, 2000: 1010.
35   Chen XQ, Jin YY. Pharmacology. 14th ed. Beijing: People's Medical Publishing House, 2002: 88.
36   Wang ML, Lu YM, Yu J. Inhibition of cytokine expression in mice with colitis with Kangfuxin Fluid. Chin J Clin Pharm 2006,15: 173-175.
37   Zheng Z, Chen WX. Study on the mechanism of experimental and colitis in acute rats with Kangfuxin Fluid. Gastroenterol 2008,13: 31-34.
38   Zhang FJ. Observation and mechanism of treatment of experimental colitis in rats with Kangfuxin Fluid. Guiyang: Zunyi Medical College, 2011.
39   Lu YM, Jin Y, Chen WX. Study on the Treatment of Experimental Colitis in Mice with Kangfuxin Fluid. Clin med China 2011, 18: 446-449.
40   Du WW. The Therapeutic Effect and Mechanism of Oxazole to Ulcerative Colitis in Rats with Kangfuxin Fluid. Chin J Exp Tradit Med Form 2017,23: 126-131.
41   Chen LM. The Clinical and Experimental Research of the Extract AT2 from Cockroach. Chin J Integr Med1986, 5: 647-650+643.
42   Li SS, Li YG, Peng SZ. The effect of Kangfuxing Fluid on the Rehabilitation of the Rabbit. J clin Exp Med 2006, 5: 730-731.
43   He ZC, Peng F, Song LY, et al. The Research Progress of Chemical Composition and Pharmacological Action of the Extract of the Periplaneta Americana. China J Chin Mater Med 2007, 32: 2326-2631.
[1] Ruijin Qiu, Changming Zhong, Huichan Yuan, Xiaoyi Tang, Ya Huang, Tianmai He, Songjie Han, Manke Guan, Min Li, Jiayuan Hu, Xiaoyu Zhang, Jing Chen, Hongcai Shang. Wenxin granule for cardiac arrhythmia: an overview of systematic reviews[J]. TMR Modern Herbal Medicine, 2019, 2(2): 91-114.
[2] Yu Yan-Hong, Chen Jing-He, Yang Qian-Chun. Acupuncture for hyperlipidaemia in adults: A systematic review and meta-analysis[J]. TMR Modern Herbal Medicine, 2018, 1(2): 74-101.